Clinical trials: Advanced Solid Tumors
Solid Tumor
Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
This is an open-label, Phase 1, dose escalation study of oral ARQ 736 administered to subjects with advanced solid tumors harboring the mutation.
- Trial name
- NCT01225536
- Testing
- ARQ 736
- Where
- 4 sites in United States, Italy
- Volunteers
- 24 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Advanced Solid Tumours
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
This is a phase Ib/II, open-label multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with…
- Trial name
- NCT03421353
- Testing
- AZD9150, Durvalumab, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 76 people
- Sponsor
- AstraZeneca
Solid Tumors
Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
BPI-9016M is a novel, highly potent and selective small-molecule inhibitor of c-Met/Axl kinase. In preclinical studies, it demonstrated strong activity in vitro and in vivo against c-Met/Axl kinase and its downstream signaling…
- Trial name
- NCT02478866
- Testing
- BPI-9016M
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Tumor, Adult
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.
- Trial name
- NCT05689853
- Testing
- AK119, AK112
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Akeso
Solid Tumor (Phase I)
A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration
This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.
- Trial name
- NCT07718165
- Testing
- ABSK211
- Where
- China
- Volunteers
- 247 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Advanced Solid Tumor
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AEs) and serious adverse events (SAEs) , pharmacokinetic parameters and antitumor effect of TQB3823 tablets in Chinese adult…
- Trial name
- NCT05021367
- Testing
- TQB3823 tablets
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors
This prospective, multicenter, non-interventional, observational, real-world study was designed to evaluate the safety and efficacy of an adebrelimab-based regimen in patients with advanced solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Gastrointestinal Cancers
- Trial name
- NCT07173244
- Testing
- Adebrelimab
- Volunteers
- 300 people
- Sponsor
- Tianjin First Central Hospital
Advanced Solid Tumor
Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors
MetaboMed is developing MTB-9655, an orally bioavailable, first-in-class small molecule inhibitor of the human Acetyl coenzyme A (Acyl-CoA) synthetase short chain family member 2 (ACSS2) enzyme, as a potential treatment for…
- Trial name
- NCT04990739
- Testing
- MTB-9655
- Where
- 3 sites in United States, Israel
- Volunteers
- 30 people
- Sponsor
- MetaboMed Inc
Solid Tumor, Breast Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02784795
- Testing
- LY3039478, Taladegib, Abemaciclib
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 94 people
- Sponsor
- Eli Lilly and Company
Malignant Neoplasm, Solid Tumors
Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
The purpose of this research study is to test the safety of chloroquine in combination with carboplatin and gemcitabine and see what effects (good and bad) it has on advanced solid tumors.
- Trial name
- NCT02071537
- Testing
- Chloroquine, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Cincinnati
Solid Cancers
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT01075464
- Testing
- MEGF0444A, bevacizumab, paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumor
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
This is a phase Ib/II study to evaluate the safety, tolerability, PK profile and preliminary efficacy of fruquintinib monotherapy or plus sintilimab for advanced solid tumors.
- Trial name
- NCT03903705
- Testing
- Fruquintinib in Combination with Sintilimab
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Hutchmed
Advanced Solid Tumor, Endometrial Carcinoma
First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors
For most advanced solid tumors, current therapy is inadequate at improving quality of life, slowing progression of disease, prolonging survival, and providing a cure.
- Conditions
- Advanced Solid Tumor, Endometrial Carcinoma, Hormone Receptor Positive
- Trial name
- NP137 (NCT02977195)
- Testing
- NP137 DL and RP2D
- Where
- 3 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Leon Berard
Solid Tumors, Adult
A Study of GC203 TIL in Advanced Solid Tumors (NF)
This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.
- Trial name
- NCT07256756
- Testing
- GC203 TIL
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai Juncell Therapeutics
Unspecified Adult Solid Tumor, Protocol Specific
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
This phase I trial studies the side effects and best dose of dabrafenib and pazopanib hydrochloride when given together in treating patients with advanced malignant tumors.
- Trial name
- NCT01713972
- Testing
- dabrafenib, pazopanib hydrochloride, Correlative studies
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Manisha Shah
Solid Tumor
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors
This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.
- Trial name
- NCT03757936
- Testing
- HLX04, HLX10
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Henlius Biotech
Unspecified Adult Solid Tumor, Protocol Specific
Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of entolimod in treating patients with locally advanced or metastatic solid tumors that cannot be removed by surgery.
- Trial name
- NCT01527136
- Testing
- entolimod, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Neoplasms, Solid Tumors
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in…
- Conditions
- Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor
- Trial name
- NCT00960063
- Testing
- Temozolomide, Vincristine, Ifosfamide
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors, Adult
Study of ON 123300 in Patients With Advanced Cancer
This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.
- Trial name
- NCT04739293
- Testing
- ON123300
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Traws Pharma, Inc.